[Federal Register Volume 84, Number 189 (Monday, September 30, 2019)]
[Notices]
[Page 51588]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2019-21138]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Centers for Disease Control and Prevention
Healthcare Infection Control Practices Advisory Committee
(HICPAC)
AGENCY: Centers for Disease Control and Prevention (CDC), Department of
Health and Human Services (HHS).
ACTION: Notice of meeting.
-----------------------------------------------------------------------
SUMMARY: In accordance with the Federal Advisory Committee Act, the CDC
announces the following meeting for the Healthcare Infection Control
Practices Advisory Committee (HICPAC). This meeting is open to the
public, is limited only by room seating available (120). The public is
also welcome to listen to the meeting via teleconference at 888-769-
9417, passcode: 4538315; 100 teleconference lines are available. Time
will be available for public comment. The public is welcome to submit
written comments in advance of the meeting.
DATES: The meeting will be held on November 14, 2019, 9:00 a.m. to 5:00
p.m., EST, and November 15, 2019, 9:00 a.m. to 12:00 p.m., EST.
ADDRESSES: Centers for Disease Control and Prevention, Global
Communications Center, Building 19, Auditorium B, 1600 Clifton Road NE,
Atlanta, Georgia 30329 and teleconference at 888-769-9417, passcode:
4538315.
FOR FURTHER INFORMATION CONTACT: Koo-Whang Chung, M.P.H., HICPAC,
Division of Healthcare Quality Promotion, NCEZID, CDC, l600 Clifton
Road NE, Mailstop H16-3, Atlanta, Georgia 30329 Telephone (404) 498-
0730. Email: [email protected].
SUPPLEMENTARY INFORMATION:
Public Comment: Comments should be submitted in writing by email to
the contact person listed below. The deadline for receipt of written
public comment is October 31, 2019. All requests must contain the name,
address, and organizational affiliation of the speaker, as well as the
topic being addressed. Written comments should not exceed one single-
spaced typed page in length and delivered in 3 minutes or less. Members
of the public who wish to provide public comments should plan to attend
the public comment session at the start time listed. Please note that
the public comment period may end before the time indicated, following
the last call for comments. Written comments received in advance of the
meeting will be included in the official record of the meeting.
Registration is required to attend in person or on the phone.
Interested parties must be processed in accordance with established
federal policies and procedures and may register at https://www.cdc.gov/hicpac.
Purpose: The Committee is charged with providing advice and
guidance to the Director, Division of Healthcare Quality Promotion
(DHQP), the Director, National Center for Emerging and Zoonotic
Infectious Diseases (NCEZID), the Director, CDC, and the Secretary,
Health and Human Services, regarding (1) the practice of healthcare
infection prevention and control; (2) strategies for surveillance,
prevention, and control of infections, antimicrobial resistance, and
related events in settings where healthcare is provided; and (3)
periodic updating of CDC guidelines and other policy statements
regarding prevention of healthcare-associated infections and
healthcare-related conditions.
Matters to be Considered: The agenda will include updates on CDC's
activities for prevention of healthcare-associated infections. It will
also include updates from the following HICPAC workgroups: The
Healthcare Personnel Guideline Workgroup and the Neonatal Intensive
Care Unit (NICU) Guideline Workgroup. The agenda also includes updates
on CDC and DHQP activities. Agenda items are subject to change as
priorities dictate.
The Director, Strategic Business Initiatives Unit, Office of the
Chief Operating Officer, Centers for Disease Control and Prevention,
has been delegated the authority to sign Federal Register notices
pertaining to announcements of meetings and other committee management
activities, for both the Centers for Disease Control and Prevention and
the Agency for Toxic Substances and Disease Registry.
Kalwant Smagh,
Director, Strategic Business Initiatives Unit, Office of the Chief
Operating Officer, Centers for Disease Control and Prevention.
[FR Doc. 2019-21138 Filed 9-27-19; 8:45 am]
BILLING CODE 4163-18-P